Brokerages Set Stemline Therapeutics, Inc. (STML) Price Target at $33.40
Stemline Therapeutics, Inc. (NASDAQ:STML) has received a consensus rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.40.
STML has been the subject of several research analyst reports. HC Wainwright set a $34.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st.
A number of institutional investors have recently modified their holdings of the business. Empire Life Investments Inc. bought a new stake in Stemline Therapeutics in the third quarter worth about $373,000. Cowen Inc. bought a new stake in Stemline Therapeutics in the third quarter worth about $420,000. Lyon Street Capital LLC raised its position in Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after acquiring an additional 415,867 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Stemline Therapeutics by 82.0% in the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock worth $2,434,000 after acquiring an additional 98,775 shares in the last quarter. Finally, C WorldWide Group Holding A S bought a new stake in Stemline Therapeutics in the third quarter worth about $1,776,000. Hedge funds and other institutional investors own 50.24% of the company’s stock.
Stemline Therapeutics (NASDAQ STML) traded down $0.40 during mid-day trading on Friday, reaching $15.15. 192,535 shares of the company traded hands, compared to its average volume of 275,924. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $15.95.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.